POZEN Inc.
News and overview for POZEN Inc.
POZEN Announces Start of Enrollment For PA32540 Phase 3 Program [Press Release]
Business Wire | 3 days 20 hours 53 minutes ago
POZEN Inc. (NASDAQ: POZN) announced today the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.
POZEN Reports Third Quarter 2009 Results [Press Release]
Business Wire | 26 days 22 hours 53 minutes ago
POZEN Inc. (NASDAQ: POZN), today announced results for the third quarter ended September 30, 2009.
POZEN Announces October 28, 2009 Webcast of Third Quarter 2009 Results [Press Release]
Business Wire | 40 days 22 hours 53 minutes ago
POZEN Inc. (NASDAQ: POZN), announced today that it will release third quarter 2009 results on October 28, 2009, before the market opens.
POZEN To Present at the Credit Suisse Healthcare Conference [Press Release]
Business Wire | 24 days 22 hours 53 minutes ago
POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka, Pharm.D., the Company’s Chairman, President and Chief Executive Officer, will present at the Credit Suisse Healthcare Conference on Friday, November 13, 2009 at 8:30 a.m. (PT), at the Arizona Biltmore hotel in Phoenix. Dr. Plachetka’s presentation will be webcast and archived on POZEN’s home page at www.pozen.com.
POZEN announces Phase I study results of PA65020
News-Medical.Net | 27 days 3 hours 5 minutes ago
POZEN Inc. (NASDAQ: POZN) announced today the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin (EC-ASA) and immediate-release omeprazole known as PA65020, is associated with a significantly decreased risk of GI mucosal damage compared to analgesic doses (650 mg twice daily) of over-the-counter enteric-coated aspirin (EC-ASA) in healthy adults treated for one month
Results of Phase I Study Show Novel, Investigational PA65020 Compound Significantly Decreased Risk of Upper GI Damage in Healthy Adults [Press Release]
Business Wire | 27 days 21 hours 53 minutes ago
POZEN Inc. (NASDAQ: POZN) announced today the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin (EC-ASA) and immediate-release omeprazole known as PA65020, is associated with a significantly decreased risk of GI mucosal damage compared to analgesic doses (650 mg twice daily) of over-the-counter enteric-coated aspirin (EC-ASA) in healthy adults treated for one month. The randomized, double-blind study highlighted that the majority of patients...
Patients Taking VIMOVO(TM) Showed a Decrease in Incidence of NSAID-Associated Ulcers [Press Release]
PRNewswire | 35 days 16 hours 23 minutes ago
PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- AstraZeneca
Zacks Bull and Bear of the Day Highlights: Pozen, Inc., Hain Celestial, Equity Residential, Fannie Mae and Freddie Mac [Press Release]
Business Wire | 42 days 13 hours 23 minutes ago
Zacks Equity Research highlights Pozen, Inc. (Nasdaq: POZN) as the Bull of the Day and Hain Celestial (Nasdaq: HAIN) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Equity Residential (NYSE: EQR), Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE).
Zacks Analyst Blog Highlights: Pozen, Sanofi-Aventis, Bristol-Myers, AstraZeneca and ADC Telecommunications Inc. [Press Release]
Business Wire | 12 hours 23 minutes ago
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pozen (Nasdaq: POZN), Sanofi-Aventis (NYSE: SNY), Bristol-Myers (NYSE: BMY), AstraZeneca (NYSE: AZN) and ADC Telecommunications Inc. (Nasdaq: ADCT).
Pozen hits on profit, misses on revenue
American City Business Journals | 26 days 18 hours 56 minutes ago
Pozen Inc. on Wednesday reported it had topped Wall Street estimates for third quarter earnings but fell just short on revenue.
New Combination Drug Improves Gastroprotection, Adherence Compared With EC Naproxen Alone
Medscape (free registration) | 17 days 15 hours 36 minutes ago
PN400 (Vimovo, Pozen Inc, AstraZeneca), an investigational drug consisting of immediate-release esomeprazole 20 mg and enteric-coated (EC) naproxen 500 mg, reduces the incidence of nonsteroidal anti-inflammatory drug (NSAID)–associated gastric ulcers for patients on long-term NSAID maintenance therapy who are at risk, according to 2 phase 3 studies presented here at the American College of Gastroenterology 2009 Annual Scientific Meeting.
ACR Drafts Treatment Guidelines for Knee, Hip, and Hand Osteoarthritis
Medscape (free registration) | 32 days 15 hours 21 minutes ago
: Preliminary treatment recommendations for hand, hip, and knee osteoarthritis presented at the American College of Rheumatology annual meeting await final approval.
Nov. 10
HBS Working Knowledge | 13 days 19 hours ago
First Look Each week First Look summarizes new working papers, case studies, and publications produced by Harvard Business School faculty.
13 Results
Sign up for USTelecom dailyLead
Company Overview
| Company: | POZEN Inc. |
|---|---|
| Industry: | Pharmaceuticals Manufacturers |
| Website: | http://www.pozen.com |
POZEN is no poseur when it comes to its single-minded focus on pain management. The drug development company is creating what it hopes will be better treatments for pain and pain-related conditions. In 2008 it won FDA approval for adult migraine treatment Treximet, which it developed in partnership with GlaxoSmithKline; GlaxoSmithKline has commercialization rights to the drug. The company is also working on a combination drug with AstraZeneca that may treat the pain and inflammation of osteoarthritis with fewer gastrointestinal side effects than existing treatments. It has licensed US rights to another pain treatment called lornoxicam from Nycomed.
Key Numbers
| Sales in U.S. Dollars (mil.) | 66.1 (2008) |
|---|---|
| One-year % Growth in Sales | 23.7 (2008) |
| Net Income in U.S. Dollars (mil.) | -6 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 34 (2008) |
| One-year % Growth in Number of Employees | -2.9 (2008) |
| Fiscal Year-End | December |